CA2777899C - Composition for inhalation comprising a pharmaceutically acceptable glassy matrix - Google Patents

Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Download PDF

Info

Publication number
CA2777899C
CA2777899C CA2777899A CA2777899A CA2777899C CA 2777899 C CA2777899 C CA 2777899C CA 2777899 A CA2777899 A CA 2777899A CA 2777899 A CA2777899 A CA 2777899A CA 2777899 C CA2777899 C CA 2777899C
Authority
CA
Canada
Prior art keywords
composition
metal ion
calcium lactate
ion salt
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2777899A
Other languages
English (en)
French (fr)
Other versions
CA2777899A1 (en
Inventor
Glen Martyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innovata Ltd
Original Assignee
Innovata Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovata Ltd filed Critical Innovata Ltd
Publication of CA2777899A1 publication Critical patent/CA2777899A1/en
Application granted granted Critical
Publication of CA2777899C publication Critical patent/CA2777899C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2777899A 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix Active CA2777899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0918450.8 2009-10-21
GBGB0918450.8A GB0918450D0 (en) 2009-10-21 2009-10-21 Composition
PCT/GB2010/001955 WO2011048379A2 (en) 2009-10-21 2010-10-21 Composition

Publications (2)

Publication Number Publication Date
CA2777899A1 CA2777899A1 (en) 2011-04-28
CA2777899C true CA2777899C (en) 2016-03-29

Family

ID=41426476

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2777899A Active CA2777899C (en) 2009-10-21 2010-10-21 Composition for inhalation comprising a pharmaceutically acceptable glassy matrix

Country Status (7)

Country Link
US (1) US20130004542A1 (cg-RX-API-DMAC7.html)
EP (1) EP2490670B1 (cg-RX-API-DMAC7.html)
JP (1) JP2013508344A (cg-RX-API-DMAC7.html)
CN (1) CN102665684A (cg-RX-API-DMAC7.html)
CA (1) CA2777899C (cg-RX-API-DMAC7.html)
GB (1) GB0918450D0 (cg-RX-API-DMAC7.html)
WO (1) WO2011048379A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
RU2577698C2 (ru) 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
GB0908129D0 (en) * 2009-05-12 2009-06-24 Innovata Ltd Composition
WO2012030645A1 (en) 2010-08-30 2012-03-08 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9061352B2 (en) 2010-08-30 2015-06-23 Pulmatrix, Inc. Dry powder formulations and methods for treating pulmonary diseases
CA2812414C (en) 2010-09-29 2020-09-22 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
US9433576B2 (en) 2010-09-29 2016-09-06 Pulmatrix, Inc. Cationic dry powders
US20150165038A1 (en) * 2012-02-10 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and sorbitol
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
EA036153B1 (ru) * 2012-07-05 2020-10-06 Арвен Айлак Санайи Ве Тиджарет А.С. Фармацевтическая композиция для ингаляции, упакованная дозированная форма, капсула, способ лечения обструктивных заболеваний дыхательных путей и фармацевтический набор
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
WO2014074797A1 (en) * 2012-11-09 2014-05-15 Civitas Therapeutics, Inc. Ultra low density pulmonary powders
BR112015015421A2 (pt) * 2012-12-27 2017-07-11 Microdose Therapeutx Inc métodos e composições para a administração de oxibutinina
US10454088B2 (en) * 2012-12-27 2019-10-22 3M Innovative Properties Company Electrochemical device and method of making the same
EP2981247B1 (en) 2013-04-01 2023-06-07 Pulmatrix Operating Company, Inc. Tiotropium dry powders
JP2015116367A (ja) * 2013-12-19 2015-06-25 重人 下山 寝具装置、寝具装置制御方法及びプログラム
CN103830194A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗固体分散体及含有其的药物组合物
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
WO2017100656A1 (en) * 2015-12-11 2017-06-15 Otitopic Inc. Dry powder formulations of aspirin for inhalation
WO2019139479A1 (en) * 2018-01-11 2019-07-18 Rob Janssen Compositions and methods for the treatment of lung emphysema and other forms of copd
GB201817861D0 (en) * 2018-11-01 2018-12-19 Nicoventures Trading Ltd Gel and crystalline powder
JP2025503459A (ja) * 2021-12-16 2025-02-04 アルヴィアラス バイオ,インコーポレイテッド 疾患の治療のための噴霧乾燥された吸入可能なバイオ治療剤
CN115046816B (zh) * 2022-03-11 2025-09-26 桂林优利特医疗电子有限公司 一种尿液有形成分分析仪用结晶质控物的制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8802174D0 (en) * 1988-02-01 1988-03-02 Quadrant Bioresources Ltd Method of drying macromolecules
WO1990011756A1 (en) 1989-04-12 1990-10-18 Aberdeen University Slow release vitreous systems
GB9107628D0 (en) 1991-04-10 1991-05-29 Moonbrook Limited Preparation of diagnostic agents
EP0563455A1 (en) 1992-03-31 1993-10-06 Purac Biochem B.V. Particulate solid products containing a lump forming inhibitor
DE69332240T2 (de) * 1992-06-12 2003-04-10 Teijin Ltd., Osaka Ultrafeines pulver zur inhalation und dessen herstellung
ES2316917T3 (es) 1994-03-07 2009-04-16 Nektar Therapeutics Metodos y composiciones para suministro pulmonar de insulina.
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
JP3095624B2 (ja) 1994-07-19 2000-10-10 株式会社ボッシュオートモーティブシステム 積層型熱交換器の偏平チューブのろう付け方法
CZ297431B6 (cs) 1994-08-04 2006-12-13 Quadrant Holdings Cambridge Limited Prostredek obsahující dodávací systém pevné dávkypro prímou aplikaci v pevné forme a zpusob jeho výroby
GB9423419D0 (en) 1994-11-19 1995-01-11 Andaris Ltd Preparation of hollow microcapsules
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
MX9709716A (es) 1995-06-07 1998-03-31 Quadrant Holdings Cambridge Metodos para incorporar substancias estables dentro de matrices de vidrio celular secas y composiciones obtenidas mediante los mismos.
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
GB9621825D0 (en) 1996-10-19 1996-12-11 Andaris Ltd Microparticles and their use as therapeutic vehicles
WO1999047174A1 (en) 1998-03-18 1999-09-23 Cambridge Biostability Limited Amorphous glasses for stabilising sensitive products
ATE382386T1 (de) 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
ATE363892T1 (de) 1999-03-05 2007-06-15 Chiesi Farma Spa Verbesserte pulverformulierungen zur inhalation
UA75375C2 (en) 2000-10-12 2006-04-17 Boehringer Ingelheim Pharma Method for producing powdery preparations for inhaling
DE10050995A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10050994A1 (de) 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
US20020141946A1 (en) * 2000-12-29 2002-10-03 Advanced Inhalation Research, Inc. Particles for inhalation having rapid release properties
DE10141376A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Inhalationspulvern
DE10141377A1 (de) 2001-08-23 2003-03-13 Boehringer Ingelheim Pharma Aufstreuverfahren zur Herstellung von Pulverformulierungen
JP2003062074A (ja) * 2001-08-29 2003-03-04 Tomohiko Hashiba 吸入装置
DE10203749A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Anticholinergika, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203753A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10203741A1 (de) 2002-01-31 2003-08-14 Boehringer Ingelheim Pharma Neue Fluorencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US20050152845A1 (en) * 2002-02-04 2005-07-14 Keith Biggadike Amorphous fluticasone 2-furoate, pharmaceutical compositions thereof and its conversion to the crystalline unsolvated form
JP2005520847A (ja) 2002-03-20 2005-07-14 アドバンスト インハレーション リサーチ,インコーポレイテッド 肺投与用hGH(ヒト成長ホルモン)製剤
US20050053666A1 (en) 2002-12-31 2005-03-10 Stelios Tzannis Antibody-containing particles and compositions
JP2005060330A (ja) * 2003-08-18 2005-03-10 Tomohiko Hashiba 球状タンパク質粉体とその製造方法
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
RU2577698C2 (ru) * 2009-03-26 2016-03-20 Пулмэтрикс, Инк. Сухие порошкообразные составы и способы лечения легочных заболеваний
JP2012522012A (ja) * 2009-03-26 2012-09-20 パルマトリックス,インコーポレイテッド 粘膜内層の生物物理学的性質の改変のためのクエン酸カルシウムおよび乳酸カルシウム製剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10589039B2 (en) 2012-02-29 2020-03-17 Pulmatric Operating Company, Inc. Methods for producing respirable dry powders

Also Published As

Publication number Publication date
CA2777899A1 (en) 2011-04-28
WO2011048379A3 (en) 2012-01-05
CN102665684A (zh) 2012-09-12
GB0918450D0 (en) 2009-12-09
WO2011048379A2 (en) 2011-04-28
EP2490670A2 (en) 2012-08-29
JP2013508344A (ja) 2013-03-07
EP2490670B1 (en) 2019-04-17
US20130004542A1 (en) 2013-01-03

Similar Documents

Publication Publication Date Title
CA2777899C (en) Composition for inhalation comprising a pharmaceutically acceptable glassy matrix
EP2429497B1 (en) Process for preparing microparticles
US9011923B2 (en) Suspension formulations
ES2650663T3 (es) Proceso y producto para inhalación que comprende glicopirrolato
US9907754B2 (en) Taurine compositions suitable for inhalation
JP5318119B2 (ja) 吸入器
JP2011523861A (ja) 吸入器
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
JP5833824B2 (ja) 吸入器
US20240123168A1 (en) Product delivery devices and methods
JP2005519095A (ja) 新規製剤
CN111481550A (zh) 含有噻托溴铵和阿福特罗的药物制剂
KR102898819B1 (ko) 흡입용 건조 분말 제제를 위한 신규 담체 입자

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140320